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Abstract
Introduction: The aim of this study was to assess the feasibility of diagnosing early rheumatoid arthritis (RA) by
measuring selected metabolic biomarkers.
Methods: We compared the metabolic profile of patients with RA with that of healthy controls and patients with
psoriatic arthritis (PsoA). The metabolites were measured using two different chromatography-mass spectrometry
platforms, thereby giving a broad overview of serum metabolites. The metabolic profiles of patient and control
groups were compared using multivariate statistical analysis. The findings were validated in a follow-up study of RA
patients and healthy volunteers.
Results: RA patients were diagnosed with a sensitivity of 93% and a specificity of 70% in a validation study using
detection of 52 metabolites. Patients with RA or PsoA could be distinguished with a sensitivity of 90% and a
specificity of 94%. Glyceric acid, D-ribofuranose and hypoxanthine were increased in RA patients, whereas histidine,
threonic acid, methionine, cholesterol, asparagine and threonine were all decreased compared with healthy
controls.
Conclusions: Metabolite profiling (metabolomics) is a potentially useful technique for diagnosing RA. The
predictive value was without regard to the presence of antibodies against cyclic citrullinated peptides.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease in
which the synovial tissues of the affected joints are invaded
by cells of the immune system [1,2]. Primarily the hands
and feet are affected, but other joints may be progressively
involved. Patients with RA experience a progressive
destruction of the affected joints, leading to disability.
There have been substantial advances in the understand-
ing of the disease pathogenesis, which has led to important
improvements in the treatment of RA, most notably the
introduction of biological disease modifiers such as tumor
necrosis factor-a (TNF-a) inhibitors [3]. However, since
the aetiology, apart from the identification of some genes
associated with the disease, remains largely unknown, cau-
sal treatment is basically unavailable.
Even though the value of early intervention in RA has
been appreciated for a long time, the diagnostic criteria
applied for a diagnosis of RA are less appropriate in
early disease [4,5]. This situation has been improved by
realization of the value of detecting antibodies against
cyclic citrullinated peptides and/or proteins (ACPA) in
the identification of individuals likely to develop RA,
even years before the manifestation of disease symptoms
[6]. The presence of ACPA has been suggested to pre-
dict more severe disease [7-9]; however, not all RA
patients are seropositive for ACPA, and in some patients
diagnosis remains difficult, which can lead to delays in
the initiation of the appropriate treatment. Several com-
mercially available tests based on the detection of ACPA
have been introduced, but they are problematic for diag-
nostic purposes, since they are not a prerequisite for the
development of RA. Normally, to achieve a specificity of
98%, any test needs to have a sensitivity of <75%; hence
their use can lead to a significant proportion of false-
negative results [10].
Metabolic profiling (metabolomics) is an approach
that could facilitate a more general and robust diagnosis
and consequently an improved prognosis. Metabolic
* Correspondence: johan.trygg@chem.umu.se
1Computational Life Science Cluster (CLiC), Department of Chemistry, Umeå
University, SE-90187 Umeå, Sweden
Full list of author information is available at the end of the article
Madsen et al. Arthritis Research & Therapy 2011, 13:R19
http://arthritis-research.com/content/13/1/R19
© 2011 Madsen et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.profiling has been used to identify biomarkers for sev-
eral diseases [11]. The fundamental rationale in metabo-
lomics is that perturbations in a biological system, for
instance, those caused by a disease, will be detectable as
changes in concentrations of certain metabolites. In
some cases (for example, congenital metabolic diseases),
it may be possible to identify a single, robust diagnostic
metabolite, but in many cases the perturbations are
more subtle, involving the activation of multiple enzy-
matic pathways. In such cases, it is unlikely that any sin-
gle biomarker will be sufficiently specific for diagnostic
purposes. However, by using multivariate statistics, it
m a yb ep o s s i b l et od e s c r i b ep a t t e r n so fb i o m a r k e r st h a t
are highly discriminatory for the perturbation and/or
disease state [12,13]. An additional advantage of diag-
nosing patients using a metabolomic strategy is the pos-
sibility of revealing underlying biochemical phenomena
associated with the disease, thus providing insights that
help the development of a better understanding of the
disease state.
The aim of this study was to assess the value of meta-
bolic profiling in the diagnosis of patients with early RA
by discriminating RA patients from healthy controls
using multivariate analysis of the data for the measured
metabolites. Patients with RA were also compared with
psoriatic arthritis (PsoA) patients to evaluate the specifi-
city of the metabolic changes in RA.
Materials and methods
An overview of the experimental setup in this study is
presented in Figure 1. Details of the analytical and data-
processing procedures are in the supplementary infor-
mation in Additional file 1 [14-20].
Clinical sampling
Study 1
Blood samples were collected from 25 patients with RA
according to the American College of Rheumatology
(ACR) 1987 criteria [21] and from 20 patients fulfilling
the Moll and Wright classification criteria [22], as well as
the newly proposed CASPAR (Classification Criteria for
Psoriatic Arthritis) classification criteria for established
PsoA [23]. All patients were attending the Rheumatology
Clinic at Umeå University Hospital, Umeå, Sweden. The
corresponding serum samples were stored at -80°C until
analysis. Of the RA patients, 17 (12 females and five
males) had a disease duration of less than 1 year (mean, 6
months), with a mean age (± SD) of 51.1 (± 17.8) years
(range, 18 to 76 years of age), and seven were ACPA-ser-
opositive as analysed using the Diastat kit from Axis-
Shield Diagnostics Limited (The Technology Park, Dun-
dee, UK) for anti-cyclic citrullinated peptide 2 (anti-
CCP2). The other eight RA patients (four females and
four males) with established disease had a mean (± SD)
disease duration of 18.8 (± 9.4) years and a mean age of
50.3 (± 17.6) years (range, 26 to 77 years of age), and all
were ACPA-positive. Nine of the patients with early RA
were treated with disease-modifying antirheumatic drugs
(DMARDs) (five received methotrexate, three received
sulfasalazine and one received hydroxychloroquine), as
were two of the patients with established RA (one was
receiving methotrexate together with a TNF inhibitor,
and one was receiving methotrexate and hydroxychloro-
quine). Four patients in each of the early and established
RA groups were prescribed corticosteroids (mean daily
dose of 8.75 mg of prednisolone). The mean (± SD) Dis-
ease Activity Score 28 (DAS28) [24] for the patients was
4.06 (± 1.16) and ranged from 2.03 to 6.72.
All 20 patients (10 female and 10 male) with PsoA
were seronegative for ACPA and rheumatoid factor (RF)
and predominantly had peripheral arthritis. Three of the
patients had mono- or oligoarthritis, and 17 patients
had polyarthritis. Five of the patients also presented
with axial disease. The mean (± SD) age of the PsoA
patients was 48 (± 12) years (range, 31 to 68 years of
age) with a mean (± SD) duration of 15 (± 12) years for
joint disease and 20 (± 11) years for skin disease. Six of
the patients were treated with DMARDs (three with
methotrexate, two with cyclosporine and one with sulfa-
salazine), and five were prescribed nonsteroidal anti-
inflammatory drugs.
Figure 1 Overview of the metabolic profiling study.T h ef i g u r e
lists the consecutive steps in this study that allowed the diagnosis
of RA patients and the identification of discriminative metabolites.
Details of analytical and data-processing procedures can be found
in the supplementary information in Additional file 1.
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female) recruited from the population register of the
county of Västerbotten, Sweden, with a mean age of
55.2 years (range, 44 to 69 years).
Two different types of metabolite profiling were car-
ried out, and full data were obtained for 21 of the RA
p a t i e n t s ,n i n eo ft h ec o n t r o l sa n d1 7o ft h eP s o A
patients.
Validation study
The validation study was performed using separate RA
and control cohorts collected at different global sites,
thereby providing an assessment of the general applic-
ability of the metabolite profiles. Four patients were
attending the rheumatology department, Lund, Sweden,
whilst 10 were from rheumatology departments in Rus-
sia (Institute of Rheumatology, City Clinical Hospital
and Municipal Clinical Hospital, Moscow, and State
Medical University, St. Petersburg).
All 14 RA patients (10 female and four male) fulfilled
at least four criteria for RA as defined by the ACR [21],
and the mean age of the group was 58.1 years (range, 45
to 76 years of age). Four patients were being treated
with a combination of methotrexate and corticosteroids,
three with methotrexate alone and two with corticoster-
oids. The mean (± SD) DAS28 [24] for this cohort of
patients was 5.82 (± 0.74) and ranged between 4.50 and
7.00.
The 20 controls, all males, were healthy volunteers
recruited through advertisement by the Karolinska
University Hospital, Stockholm, Sweden. Their mean
age was 26.0 years (range, 20 to 45 years of age).
Both Study 1 and the validation study were approved
by the relevant regional ethics committees of the institu-
tions involved, and all participants gave their written
informed consent.
Statistical analysis
Multivariate modeling
Chemometrics includes efficient and robust methods for
the analysis of large multivariate data tables that pro-
duce interpretable and reliable prediction models. In
biology, chemometric methodology has been largely
overlooked in favour of traditional statistics. It has not
been until recently that the overwhelming size and com-
plexity of the ‘omics’ technologies have driven biology
towards adopting chemometric analysis [13].
Orthogonal projections to latent structures-
discriminant analysis (OPLS-DA) [18,20] is a multivari-
ate classification technique used for finding patterns in
large multivariate data sets that describe differences
between the groups under study. The OPLS-DA model
can map and separate all disease discriminating variation
(predictive variation) from the variation that is uncorre-
lated to disease discrimination (orthogonal variation).
Examples of orthogonal variation can be related to sex,
age, sampling and experimental issues. OPLS-DA model
interpretation is straightforward as the correlation (p
(corr)) provides a direct measure of the discriminatory
capability of each metabolite [25].
In this study, RA patients were compared with healthy
controls and PsoA patients, and OPLS-DA models were
used for (1) mapping the metabolic differences between
the disease classes, (2) predicting disease in new indivi-
dual samples, and (3) finding a specific metabolic pat-
tern indicative of RA. Technical aspects of the OPLS
algorithm (the basis for OPLS-DA) have been described
fully by Trygg and Wold [18]. A technical description of
OPLS-DA, together with application studies, has been
provided by Bylesjö et al. [20].
Predicting the class of new individuals is a possible
method for diagnosing RA. This may be achieved by fit-
ting an OPLS-DA model to discriminate RA patients
from controls. A binary response variable in which “1”
indicated RA patients and “-1” indicated controls was
created (see Keun et al. [26]). Each row represents a
sample from one individual. Assignment of this binary
variable has no influence on results, but for visual clarity
it was decided to set the RA patients to positive values
throughout the study.
The models were tested using a sevenfold cross-
validation procedure in which one-seventh of all patients
were omitted from the model fitting and subsequently
predicted by the obtained model. This procedure is
repeated seven times so that all patients are left out in
turn from the modeling procedure [27]. Additional vali-
dation of the results was achieved by predicting the
diagnosis of a group of patients in a separate study (the
validation study) using the model fitted in study 1. Pre-
diction of the excluded samples gives a numerical value
that allows diagnosis. Separate models for healthy con-
trols versus RA patients and PsoA patients versus RA
patients were used.
All multivariate modeling was performed using Simca-
P+ version 12 (Umetrics, Umeå, Sweden).
Univariate statistics
All statistical tests were two-sided Student’s t-tests for
samples with equal variance. Standard scores (z-scores)
were calculated using the mean of the control group
(healthy subjects or patients with PsoA) for comparisons
between the groups. Only identified metabolites are pre-
sented in the plots and tables.
Results
Combination of the data acquired using gas chromato-
graphy-mass spectrometry and liquid chromatography-
mass spectrometry resulted in semiquantitative data
being available for 267 (study 1) and 240 (validation
study) putative metabolites. Eighty-three metabolites
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Additional file 1) and fifty-two were positively identified
in both study 1 and the validation study.
The aim of this study was to evaluate the potential for
diagnosing RA using metabolic profiling. For this pur-
posed, OPLS-DA classification models were constructed
for the discrimination between RA patients and healthy
controls and between RA patients and PsoA patients,
respectively. The results presented are predicted values
based on multivariate models using all measured meta-
bolites. The models are fitted using data from study 1,
and the results are calculated using cross-validation (see
Materials and methods) and data from the validation
study.
Predictions based on classifying RA patients versus
healthy controls in study 1 resulted in a sensitivity of
81% and a specificity of 67% (Figure 2A). RA patients
and PsoA patients were classified with a sensitivity of
90% and a specificity of 94% (Figure 2B).
The most reliable method of validating the usefulness
of metabolomic findings is to undertake a predictive
approach in an entirely different patient cohort. Conse-
quently, a validation study was carried out after evalua-
tion of study 1 using a new group of patients. Fourteen
patients with RA and 20 healthy controls had their blood
metabolites profiled, and a diagnosis of RA was predicted
using the model developed in study 1. The validation
samples were obtained from different hospitals and ana-
lysed by different personnel, thereby giving a realistic
indication of the diagnostic performance that may be
expected in future applications. When comparing two
different studies, it is necessary that the variables (meta-
bolites) in each study be identical, thus the full metabolo-
mic data set was not used in the predictions; instead,
Figure 2 Multivariate prediction of diagnosis of patients and healthy controls based on metabolite patterns. (A) Box-and-whisker plot
showing the prediction results from cross-validation in the study 1 rheumatoid arthritis (RA) versus control orthogonal projections to latent
structures-discriminant analysis (OPLS-DA) model. Negative values correspond to controls and positive values indicate RA diagnoses (see
Materials and methods). The blue outlined box denotes the median and 25% and 75% quartiles. The vertical black bars mark the median +1.5
times the interquartile range. (B) Prediction results for discrimination between RA and psoriatic arthritis patients using cross-validation.
(C) Prediction results from the follow-up study. The model was built using study 1 data (52 metabolites and nine observations from each group).
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and confirmed to be identical in the two studies. This
validation resulted in a sensitivity of 93% and a specificity
of 70% for RA (Figure 2C).
An additional aim of this study was the identification
of metabolites that would be useful for discriminating
between RA patients and controls. OPLS-DA models
allow easy identification of those metabolites that are
present in different concentrations in the groups being
compared by generating correlation values for each
metabolite. Plots showing the relative metabolite con-
centrations for each individual in the study are pre-
sented in Figures 3A and 3B. These plots are sorted
according to the correlation of the metabolite to RA
from the largest negative to the largest positive correla-
tion. Metabolites found in statistically significantly dif-
ferent concentrations, according to Student’s t-test, are
listed in Table 1. A list of mean values and standard
deviations for all identified metabolites is provided as
supplementary information (Additional file 1). Predic-
tion models built using only identified metabolites actu-
ally gave slightly better predictive results than the full
model. In the case of study 1, the sensitivity was 86%
and the specificity was 78%. This indicated that some of
the unidentified metabolites were “experimental noise”
and were not required for the diagnosis of RA.
Discussion
The aim of the present study was to assess the feasibility
of employing metabolic profiling as a tool in the diagno-
sis of RA. The sensitivity of 93% is a good result com-
pared with the tests currently available, which are based
primarily on the detection of ACPA or RF. The specifi-
city in the range of 70% to 80%, on the other hand, is
not up to par with ACPA-based tests. Further appealing
aspects of the metabolic profiling method were the cap-
ability of identifying individuals in both the early and
advanced stages of RA disease and that this method was
able to confirm the diagnosis of patients who were
ACPA-negative and who would not have been diag-
nosed using the antibody tests. Metabolic profiling of
biomarkers is therefore primarily a candidate method
for closing some of the gaps in the diagnosis of RA that
currently exist, especially with regard to ACPA-negative
Figure 3 Metabolic patterns seen in patients and healthy controls. (A) Heat map showing the standard score for the each metabolite for
each rheumatoid arthritis (RA) patient and each healthy control. The standard score shows how the concentration of each metabolite is related
to the mean value of the control group for each individual. The standard score was calculated using the mean of the controls to attenuate the
RA patients. Yellow color indicates that the metabolite is increased compared to the mean of the control group; red that it is decreased.
Metabolites are sorted according to the correlation to RA in the RA versus control orthogonal projections to latent structures-discriminant
analysis (OPLS-DA) model. The standard score is truncated to -2/2 for clarity. (B) Similar plot to Figure 3A, but showing RA and psoriatic arthritis
(PsoA) patients. The standard score was calculated using the mean of the PsoA patients to attenuate the RA patients. Yellow color indicates that
the metabolite is increased compared to the mean of the PsoA group; red that it is decreased. Metabolites are sorted according to the
correlation to RA in the RA versus PsoA OPLS-DA model. The standard score is truncated to -2/2.
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for patients without positive results in ACPA tests can
be substantially improved.
It is important to note that the prediction of a diagno-
sis of RA was based on calculations using the full data
set. The metabolites subsequently found to have the lar-
gest impact on the model are therefore the most impor-
tant in reaching the diagnosis. Since the main result of
the study is the diagnostic prediction, no correction for
multiple statistical testing was made, but it was decided
to report P values to illustrate the impact of each meta-
bolite on the final result.
The cohorts in study 1 and in the validation study
contained patients attending different clinics. It is
encouraging that similar metabolic perturbations were
detectable in RA patients from different geographical
areas. This indicates that the metabolic perturbations
seen are indeed related to RA disease processes, and
further studies including larger patient and control
cohorts are warranted to validate the biomarker profile
for clinical use, to investigate its usefulness in prognosis
and to investigate the various metabolic markers in rela-
tion to the disease process in RA.
A number of questions need further elucidation before
clinical use of metabolic markers can become relevant.
First, it is necessary to establish whether the metabolic
profile is specific for RA or whether similar metabolic
perturbations accompany other inflammatory diseases.
To investigate this question, a cohort of patients with
PsoA was included in this study. The results indicated
larger differences between the RA patients and the PsoA
patients than between the RA patients and healthy con-
trols, as judged by between-group variability and the
number of statistically significant metabolites differen-
tiating the groups. This was somewhat surprising, con-
sidering the two inflammatory diseases. To arrive at a
complete assessment of the usefulness of metabolic per-
turbations in the diagnosis of RA, any future study
should include other groups of patients with a diagnosis
other than RA, such as systemic lupus erythematosus,
polymyalgia rheumatica and gout, as well as noninflam-
matory conditions, such as osteoarthritis.
It was perhaps surprising that better diagnostic results
were achieved in the follow-up study than in study 1.
A possible explanation is that these predictions were
derived with fewer variables in the model. It is well known
that variable selection can be a useful tool for optimising
multivariate prediction models, since many of the detected
variables (in this case, metabolites) carry no systematic
information about the health status of the individual [28];
that is, they are the same in RA patients as in controls and
only introduce noise in the model. As described above,
better results were obtained in study 1 by decreasing the
number of variables in the prediction model; however, the
full data available are presented to give a more complete
picture of the findings. Selection of the most discrimina-
tory metabolites would almost certainly be required before
using a metabolic marker profile in a clinical setting, since
in these circumstances there would be a question of quan-
tifying a limited number of metabolites for practical rea-
sons. Similar diagnostic capability could be maintained
with as few as seven metabolites (data not shown). The
v a l i d a t i o ns t u d yw a sw o r s et h a ns t u d y1i nt e r m so f
matching the cases and controls, but the predictions were
made on the basis of the results of study 1, indicating that
the metabolites highlighted in study 1 were also relevant
for distinguishing the individuals in the validation study.
Another question that needs clarification is how the
metabolic profile of a patient is affected by disease activ-
ity and medical treatment. The RA patients classified as
being healthy included the patient with the lowest
DAS28 value (2.03), but the other two patients who
were wrongfully classified as healthy had average DAS28
v a l u e s( 4 . 2 2a n d5 . 0 5 ) .I ti sp o s s i b l et h a tf l u c t u a t i o n si n
disease activity might affect the metabolic profile of
patients to some degree, but in this study high disease
activity was not a prerequisite for diagnosis on the basis
of metabolic profiling.
The present study was not designed to assess the rela-
tionship of metabolites with disease activity, but an
Table 1 Metabolites found in different concentrations in
RA patients and controls and in RA patients vs. PsoA
patients
a
RA relative to control P value RA relative to PsoA P value
Increased Increased
Glyceric acid 0.029436 Glutamine 0.030049
D-ribofuranose 0.018080 Heptanoic acid 0.008232
Hypoxanthine 0.048579 Succinate 0.005375
Pseudouridine 0.030814
Inosine 0.032232
Guanosine 0.023726
Arabitol 0.004232
Cystine 0.009069
Cysteine 0.000118
Phosphoric acid 0.010883
Decreased Decreased
Histidine 0.000109 Aspartic acid 0.000090
Threonic acid 0.000784 Glutamic acid 0.000248
Methionine 0.011428 Glutamate 0.001000
Cholesterol 0.023463 Histidine 0.007315
Asparagine 0.024166 Serine 0.008824
Threonine 0.046816 Arachidonic acid 0.038373
Cholesterol 0.027836
Threonic acid 0.002215
1-Monooleoylglycerol 0.002369
aRA, rheumatoid arthritis; PsoA, psoriatic arthritis. P values are from the two-
sided Student’s t-test for samples with equal variance.
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gate whether and how DAS28 [24] is correlated to
changes in the metabolite profile. This study did include
patients on different DMARD regimens as well as non-
DMARD-treated patients. Drug treatment did not intro-
duce systematic problems in the metabolic profiling
diagnosis; it is likely, however, that a number of metabo-
lites are affected by treatment, and it would be interest-
ing to map these effects further. It is even possible that
the patient response to treatment could be correlated to
changes in metabolic profile.
It is well known that factors such as sex, age, comor-
bidity, lifestyle and circadian rhythms [29-32] can affect
the metabolic profile. This makes it important that the
method be validated in larger studies accounting for
these possible confounders before it is introduced clini-
cally. Since it is difficult to correct for these factors, the
main strategy would be to design studies that allow the
assessment of potential conditions that could impair
the diagnostic results of the method. In attempts to
ensure that the profile found in this study was robust in
terms of separating RA patients from controls, the vali-
dation study was performed using patients not attending
the same hospital clinic. This gives some confidence
that the metabolites identified are relevant to RA, but
larger prospective studies will be the best way of identi-
fying the potential role of metabolic profiling within the
field of rheumatology.
One of the fields that has driven the development of
metabolic profiling is systems biology, in which the aim
is to gain an understanding of a disease by, for example,
comparing perturbations in metabolites, proteins, gene
transcripts and genes to those found in healthy indivi-
duals [12]. Since the present study is purely a study of
metabolites, it is difficult to deduce the exact processes
behind the observed perturbation between RA patients
and controls. However, provided that these results can
be reproduced, metabolic profiling may provide a start-
ing point for mechanistic investigations into the patho-
genesis of RA.
A decreased histidine level was one of the most speci-
fic metabolic markers for RA in this study. Previous
findings have suggested that histidine catabolism is
increased in patients with RA, although the reasons for
this are unclear [33]. None of the direct products of his-
tidine metabolism were detected in this study, but this
should be the topic of a future study because of its
apparent importance in RA and it might possibly lead to
a better understanding of the pathophysiology of RA.
PsoA patients also had higher histidine levels than RA
patients, even though the difference between these
groups was smaller than that between RA patients and
controls.
Cholesterol is another compound with a well-
established link to RA. The total cholesterol level in
serum was measured in this study, therefore precluding
the possibility of commenting on the specific composi-
tion of lipoprotein particles. Our results are consistent
with an earlier report of lowered total cholesterol levels
in RA patients with active inflammation [34]. Others
have shown cholesterol levels in some groups of patients
to be inversely correlated with disease activity and that
the lipid composition in RA patients was generally unfa-
vourable [35,36].
Threonic acid, a metabolite of ascorbic acid, was
found to be significantly decreased. In the 1930s ascor-
bic acid was found to be reduced in the blood of RA
patients, although there does not appear to be any clini-
cal or pathological relevance to this observation [37].
Several amino acids were also slightly decreased in RA
patients. Histidine, methionine, asparagine and threo-
nine were found to be significantly decreased (P < 0.05),
whilst several more showed a strong negative correlation
to RA in the multivariate models. The compounds gly-
ceric acid, D-ribofuranose and hypoxanthine were
increased in RA patients. Taken together with positive
correlations of uridine, pseudouridine and guanosine,
this could indicate an increased rate of nucleotide synth-
esis, but the reasons for and relevance of this observa-
tion are hard to deduce. Furthermore, several free fatty
acids showed a strong positive correlation to RA, even
though this increase was not statistically significant.
An interesting topic for study in RA patients is the
breakdown of arginine, particularly as both inducible
nitric oxide synthases and arginase enzymes are known
to exhibit increased activity in RA [38,39]. Only a mod-
erate decrease of arginine and a slight increase of
ornithine and citrulline were detected, but none of the
effects were statistically significant. Although the exact
correlation between most of the stronger metabolic
markers for RA and the disease are unknown, it is pro-
posed that metabolomics combined with other system
biology techniques and appropriate mechanistic analysis
c a nb eah i g h l yv a l u a b l et o o lf o rr e s e a r c hi n t ot h ep r o -
cesses underlying RA and other related diseases.
Both ACPA-positive and ACPA-negative patients par-
ticipated in the study. This was mainly to ensure that
the metabolic profiling method was applicable to both
groups. No difference in the diagnostic properties of the
method was detected between the two groups. When
modeling ACPA-positive against ACPA-negative
patients, the outcomes were weaker than those seen
when modeling RA patients against controls. This indi-
cates that though there are slight metabolic differences
dependent on ACPA status, these are minor compared
with the differences introduced by RA disease per se.
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This is the first time that the usefulness of metabolic
profiling has been demonstrated in the diagnosis of RA.
It appears that the method can be developed as a com-
plementary diagnostic tool and is one that is especially
applicable to patients who are seronegative for ACPA.
Since the metabolic profile for individual patients is
highly dynamic compared with, for example, genes and
protein levels, it would be worth studying how these
metabolites correlate with disease activity. It is possible
that following the metabolite profile of individual
patients could be a tool for predicting the disease course
and thereby facilitate optimal treatment.
Additional material
Additional file 1: Supplementary Information. This document contains
supplementary information on the technical aspects of the metabolic
profiling analysis. The document also contains a list of mean values and
standard deviation for identified metabolites in study 1.
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